Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.150
34 pages

T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance

Liaomin Peng
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Peter A. Cohen
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Jorgen Kjaergaard
Center for Surgery Research, Cleveland Clinic Foundation, Cleveland, OH
Gregory E. Plautz
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
James H. Finke
Department of Immunology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA, and the Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Gary K. Koski
Division of Basic Sciences, Center for Cancer Research, National Cancer Institute at Frederick, Frederick MD 21702-1201
Brian J. Czerniecki
Department of Surgery and Harrison Surgical Research Center, University of Pennsylvania, 4th Floor Silverstein, 3400 Spruce Street, Philadelphia, PA 19104
Suyu Shu
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA


The T cells of many cancer patients are naturally sensitized to tumor-associated antigens (Ag), or they can readily be sensitized with vaccine maneuvers. In melanoma patients, the adoptive transfer of such T cells can often be causally linked to the objective regression of established tumors. So far, few patients have shown sustained clinical benefit from such therapy, but preclinical mouse studies have now clearly delineated the hurdles that must be overcome to render T-cell–based antitumor therapy effective. Contrary to earlier expectations, it is now established that remarkably potent CD4+ and CD8+ pre-effector T cells are naturally sensitized even in mice bearing progressive, weakly immunogenic tumors. However, such T cells often display signal transduction impairments as a consequence of the tumor environment, which limit their acquisition of optimal effector function. Extracorporealization and culture of these tumor-sensitized T cells with appropriate activation stimuli not only restores normal signal transduction, but also confers resolute effector activity that can often sustain tumor rejection upon reinfusion. In mouse studies, the L-selectinlow fraction of T cells in tumor-draining lymph nodes (TDLN) constitutes the potent pre-effector population and comprises both CD4+ and helper-independent CD8+ T cells. Appropriate in vitro activation confers an apparently unrestricted trafficking capacity to this fraction, and even the ability to proliferate within the tumor bed, leading to unprecedented tumor rejection at anatomic sites (e.g., subcutaneous and intracranial) that were historically refractory to such treatment. Such results underscore the surprising capacity of appropriately activated effector T cells to withstand the immunosuppressive, tolerogenic, and apoptotic influences of the typical tumor environment. Given the increasingly appreciated and critical communications between T cells and host Ag-presenting cells (APC), which cross-present tumor Ag, it is likely that dendritic cell–based vaccine maneuvers that promote sensitization of T1-committed L-selectinlow antitumimportant role in adoptive therapy strategies.

Articles with similar content:

Dendritic Cells, Interleukin 12, and CD4+ Lymphocytes in the Initiation of Class l-restricted Reactivity to a Tumor/Self Peptide
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Emira Ayroldi, Maria Laura Belladonna, Maria Cristina Fioretti, Daniela Surace, Silvia Silla, Paolo Puccetti, Ursula Grohmann, Roberta Bianchi
Peripheral CD8 T-Cell Responses to Apoptotic Cell Proteins and Peptides
Critical Reviews™ in Immunology, Vol.27, 2007, issue 4
Yu Feng Peng, Keith B. Elkon
CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection
Critical Reviews™ in Immunology, Vol.20, 2000, issue 1
Liaomin Peng, David E. Weng, Peter A. Cohen, Suyu Shu, Julian A. Kim, Gregory E. Plautz
Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell−Based Immunotherapy
Critical Reviews™ in Immunology, Vol.36, 2016, issue 6
Marco Cippitelli, Alessandra Soriani, Alessandra Zingoni, Elisabetta Vulpis, Angela Santoni, Cinzia Fionda, Ilaria Nardone
The Role of Antigen Presentation in Tumor-Associated Macrophages
Critical Reviews™ in Immunology, Vol.40, 2020, issue 3
Richard J. Stopforth, Elizabeth Sally Ward